Key result
In kidney transplant recipients treated with cyclosporine, 1-month treatment with captopril increased TGF-beta mRNA by 120% and TGF-beta1 protein release by 140% (P<0.01).
Why the study?
Does captopril enhance TGF-beta1 expression in PBMC in kidney transplant recipients treated with cyclosporine?
Population
20 kidney transplant recipients chronically treated with cyclosporine and peripheral blood mononuclear cells…
Comparison
Captopril vs Baseline (pre-treatment) and in vitro enalapril
Design
Cohort
Follow-up
1 month
Authors
Loading...
Should not yet alter captopril use in cyclosporine-treated kidney transplant recipients; leaves open effects on graft outcomes.
Does captopril enhance TGF-beta1 expression in PBMC in kidney transplant recipients treated with cyclosporine?
p-value: p=<0.01
Captopril enhances TGF-beta1 gene and protein expression in PBMC through a mechanism at least partially independent of ACE inhibition, supporting its combined use with cyclosporine in organ transplant management.
Paolo et al. (2002) studied Kidney transplant recipients chronically treated with cyclosporine (n=20). Captopril vs. Enalapril / Healthy controls was evaluated on TGF-beta mRNA and TGF-beta1 protein release upon stimulation of PBMC (p=<0.01). In kidney transplant recipients treated with cyclosporine, 1-month treatment with captopril increased TGF-beta mRNA by 120% and TGF-beta1 protein release by 140% (P<0.01).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: